Who Owns Covetrus Company?

Covetrus Bundle

Get Full Bundle:

	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

Who Owns Covetrus?

Covetrus, a significant player in animal health technology and services, underwent a major ownership change in October 2022, transitioning to private ownership via acquisition. This shift followed its establishment in 2019 through a merger.

Understanding the ownership structure is key to grasping the company's strategic direction and operational focus. The acquisition marked a new chapter for the company, impacting its future trajectory and market approach.

The primary entity that acquired Covetrus in October 2022 was Carlyle Group, a global investment firm. This acquisition marked the transition of Covetrus from a publicly traded company to a privately held one. The deal was valued at approximately $4 billion. This strategic move by Carlyle Group aimed to leverage Covetrus's established position in the animal health market and its comprehensive suite of services, including practice management software and supply chain solutions. The transaction involved significant financial backing, with Carlyle Group securing debt financing from various lenders to complete the acquisition. This privatization allows Covetrus to operate with potentially greater flexibility in its long-term strategic planning, free from the quarterly reporting pressures of public markets. The integration of Covetrus into Carlyle's portfolio is expected to drive growth and innovation within the animal health sector, building upon the company's existing strengths and expanding its reach. The acquisition was a substantial event in the private equity landscape, highlighting the continued interest in technology-enabled service businesses within specialized industries like animal health. This move also impacts how entities like those analyzed in a Covetrus PESTEL Analysis might be viewed and influenced by new ownership. The focus now shifts to how Carlyle Group will guide Covetrus's development and operational strategies moving forward.

Covetrus, a significant player in the animal health technology and services sector, was not established as a singular startup but rather through a strategic merger. Its origins trace back to the combination of Henry Schein Animal Health and Vets First Choice, with Vets First Choice being the foundational entity. This merger in February 2019 created the publicly traded company known today as Covetrus.

Vets First Choice Genesis

Vets First Choice was co-founded in 2010 by Benjamin Shaw and his father, David Shaw. David Shaw was also the founder of IDEXX Laboratories, Inc. Their initial focus was on technology-enabled healthcare services, particularly online pharmacy solutions for the animal health industry.

The Strategic Merger

In February 2019, Henry Schein, Inc. completed the spin-off of its animal health division. This division was then immediately merged with Vets First Choice, leading to the formation of Covetrus.

Initial Ownership Structure

Upon its public debut on the Nasdaq Stock Market under the ticker CVET, Henry Schein shareholders held approximately 63% of Covetrus. Vets First Choice shareholders owned the remaining 37%. This distribution aimed to balance the market presence of Henry Schein's animal health business with Vets First Choice's technological offerings.

Leadership at Inception

Benjamin Shaw took on the role of President and CEO for the newly formed Covetrus. This leadership transition underscored the integration of Vets First Choice's operational expertise into the combined entity.

Early Investment Support

Early financial backing for Vets First Choice came from investors like Clayton, Dubilier & Rice (CD&R). CD&R made an investment in Vets First Choice as early as 2015, prior to the formation of Covetrus.

Foundational Vision

The core vision driving Vets First Choice, and subsequently Covetrus, was to enhance animal healthcare through technology. This included a strong emphasis on digital platforms and services to support veterinary professionals.

The formation of Covetrus through the merger of Henry Schein Animal Health and Vets First Choice established a new corporate structure with a defined initial ownership breakdown. This strategic move combined the established market reach of one entity with the innovative technological services of the other, setting the stage for its operations as a publicly traded company. Understanding this foundational ownership is key to grasping the company's subsequent development and its position within the animal health industry. For a deeper dive into its origins, you can read about the Brief History of Covetrus.

Key Aspects of Covetrus's Founding Ownership

The initial ownership structure of Covetrus was a direct result of the merger between Henry Schein Animal Health and Vets First Choice. This created a distinct shareholder base from the outset.

• Henry Schein shareholders initially owned approximately 63% of Covetrus.
• Vets First Choice shareholders held about 37% of the new company.
• Benjamin Shaw, a co-founder of Vets First Choice, became the initial President and CEO of Covetrus.
• Early investor Clayton, Dubilier & Rice (CD&R) played a role in the pre-merger development of Vets First Choice.
• The merger aimed to leverage the strengths of both predecessor companies in the animal health market.

Covetrus SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

The ownership of Covetrus has seen a significant shift from its public market debut to its current private status. Initially listed on the Nasdaq on February 8, 2019, with an opening price of $43.05, the company's journey as a public entity was relatively short-lived.

Prior to the acquisition, Clayton, Dubilier & Rice (CD&R) already held a substantial interest, beneficially owning around 24% of Covetrus's outstanding common stock. The subsequent acquisition by CD&R and TPG Capital consolidated ownership under these two major private equity firms. As of late 2024 and into 2025, Covetrus operates as a privately held company, with its ownership primarily vested in investment funds managed by CD&R and TPG Capital. This transition to private ownership allows the company to concentrate on long-term strategic objectives without the immediate pressures of quarterly public reporting, supporting its growth in the animal health sector. This sector is projected to expand significantly, from USD 67.92 billion in 2024 to USD 119.34 billion by 2032.

Understanding Covetrus Ownership

Covetrus's ownership structure is now primarily held by two prominent private equity firms. This change impacts its operational focus and strategic direction.

• Clayton, Dubilier & Rice (CD&R) is a major stakeholder.
• TPG Capital is the other primary owner.
• The company transitioned from public to private ownership in October 2022.
• This shift allows for a focus on long-term strategic initiatives.
• The animal health sector, where Covetrus operates, is experiencing substantial growth.

Covetrus PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

Under its current private ownership, the Board of Directors of Covetrus is primarily comprised of representatives from its major private equity stakeholders, Clayton, Dubilier & Rice (CD&R) and TPG Capital. Independent directors and key management team members also hold board positions, contributing to the company's governance and strategic direction.

While specific details regarding the exact composition and voting power distribution of the private company's board are not publicly disclosed, it is understood that private equity firms like CD&R and TPG Capital typically exert substantial control. This control is exercised through their board representation and significant equity stakes, enabling them to guide strategic decisions and operational improvements with a long-term investment horizon. There have been no public reports of proxy battles or activist investor campaigns, which is characteristic of privately held companies where governance is determined by major shareholders. Understanding the Competitors Landscape of Covetrus can provide context for its strategic positioning and governance structure.

Understanding Covetrus Ownership and Control

Covetrus's ownership structure is dominated by its private equity stakeholders, influencing its strategic direction and operational decisions.

• Major stakeholders include Clayton, Dubilier & Rice (CD&R) and TPG Capital.
• The Board of Directors includes representatives from these firms, alongside management and independent directors.
• Private equity firms typically hold significant voting power, guiding long-term strategy.
• Governance details for private companies are not as transparent as for public entities.

Covetrus Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

The ownership landscape of Covetrus underwent a significant transformation in October 2022 with its privatization by Clayton, Dubilier & Rice (CD&R) and TPG Capital. This strategic move shifted the company from public trading to private equity ownership, aiming to foster long-term growth and operational enhancements.

Recent developments highlight Covetrus's ongoing investment in its operational capabilities and technological innovation, alongside leadership changes and a notable legal resolution. The company's strategic direction, now under private equity, appears focused on expanding its physical footprint and enhancing its digital offerings, as seen with the new distribution center and AI advancements. These efforts align with the broader growth trajectory of the animal health market, which was valued at approximately USD 62.89 billion in 2024 and is projected to grow at a CAGR of 10.46% from 2025 to 2030.

Infrastructure Expansion

Covetrus opened a new distribution center in Grimes, Iowa, in May 2024. This expansion aims to bolster its capacity to serve the Midwest region effectively.

Technological Advancements

The company is integrating AI-powered solutions for workflow automation and treatment boards. These innovations were showcased at the VMX 2025 conference in January 2025.

Leadership and Legal Updates

Amy Sanford joined as Global General Counsel and Chief Human Resources Officer in February 2024. Separately, a subsidiary faced legal penalties totaling over $23 million in May 2024.

Market Context

The animal health market is experiencing robust growth, driven by increased pet ownership and technological advancements. Understanding the Marketing Strategy of Covetrus provides further insight into its market positioning.

Covetrus Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔